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Abstract
Background: Cytokines secreted by the adipose tissue influence inflammation and insulin sensitivity, and lead to
metabolic disturbances. How certain single-nucleotide polymorphisms (SNPs) interfere on lifestyle interventions is
unclear. We assessed associations of selected SNPs with changes induced by a lifestyle intervention.
Methods: This 9-month intervention on diet and physical activity included 180 Brazilians at high cardiometabolic
risk, genotyped for the TNF-α -308 G/A, IL-6 -174 G/C and AdipoQ 45 T/G SNPs. Changes in metabolic and
inflammatory variables were analyzed according to these SNPs. Individuals with at least one variant allele were
grouped and compared with those with the reference genotype.
Results: In the entire sample (66.7% women; mean age 56.5 ± 11.6 years), intervention resulted in lower energy
intake, higher physical activity, and improvement in anthropometry, plasma glucose, HOMA-IR, lipid profile
and inflammatory markers, except for IL-6 concentrations. After intervention, only variant allele carriers of the
TNF-α -308 G/A decreased plasma glucose, after adjusting for age and gender (OR 2.96, p = 0.025). Regarding the
IL6 -174 G/C SNP, carriers of the variant allele had a better response of lipid profile and adiponectin concentration,
but only the reference genotype group decreased plasma glucose. In contrast to individuals with the reference
genotype, carriers of variant allele of AdipoQ 45 T/G SNP did not change plasma glucose, apolipoprotein B,
HDL-c and adiponectin concentrations in response to intervention.
Conclusion: The TNFα -308 G/A SNP may predispose a better response of glucose metabolism to lifestyle
intervention. The IL-6 -174 G/C SNP may confer a beneficial effect on lipid but not on glucose metabolism. Our
findings reinforce unfavorable effects of the AdipoQ 45 T/G SNP in lipid profile and glucose metabolism after
intervention in Brazilians at cardiometabolic risk. Further studies are needed to direct lifestyle intervention to
subsets of individuals at cardiometabolic risk.
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Introduction
Obesity-related diseases are major public health pro-
blems. Intervention programs have been based on diet-
ary changes and physical activity aiming at controlling
weight gain and prevent metabolic disturbances. Adi-
pose tissue is an important source of cytokines cap-
able to trigger inflammatory mechanisms and generate
insulin resistance, involved in the genesis of these dis-
eases [1].
Apart from the role of environmental determinants,
also genetic factors predispose to obesity and may influ-
ence the response to interventions on lifestyle. Heteroge-
neous responses to lifestyle interventions should be at
least in part controlled by genetic factors [2]. Single-
nucleotide polymorphisms (SNPs) were described in as-
sociation with the risk for obesity and metabolic diseases
[3], but how certain SNPs could interfere on the process
of weight loss is less investigated.
The tumor necrosis factor-α (TNF-α) SNP at position
-308 G/A [4] has been associated with obesity risk [5]
and increased C-reactive protein (CRP) concentrations [6].
A positive correlation between the adipose tissue mass
and expression of the gene that encodes TNF-α was
described [7]. The role of this adipocytokine in inflam-
matory response is well-established [8]. Also, TNF-α
deteriorates insulin signaling and reduces glucose uptake
[9], mediating the relationship of insulin resistance with
manifestations of the metabolic syndrome (MS) [10]. A
functional impact of G and A alleles in the synthesis of
TNF-α is controversial [11,12].
Interleukin-6 (IL-6) has also been associated with car-
diometabolic diseases; its concentrations were shown to
be predictive of type 2 diabetes (T2D) [13]. Despite
being essential for reducing acute inflammatory pro-
cesses, in chronic inflammatory states may assume a
pro-inflammatory role [14]. Adipose tissue is one of the
most important sources of IL-6 secretion, and visceral
tissue secrets 2 to 3 times more IL-6 than the subcutane-
ous tissue [13]. Associations of the −174 G/C polymorph-
ism with increased adiposity, inflammation and metabolic
disturbances have been investigated [15]. Carriers of
C allele seem to have different cardiometabolic effects
depending on body mass index (BMI). The −174 G/C
was associated with T2D in overweight individuals but
not in eutrophic ones [16]. In contrast, joint analysis,
based on data from 17 studies, suggested an association
of IL-6 G/C genotype with fasting glucose levels inde-
pendently of the BMI [17]. Moreover, C allele carriers
have shown greater IL-6 concentrations, leading to an
increase in circulating CRP [18-20]. On the other hand,
the reference genotype (G allele) was associated with
higher triglycerides, very low density lipoprotein, plasma
glucose and lower high density lipoprotein (HDL-c) con-
centrations than C allele carriers [21].
Adiponectin plays a role in energy homeostasis regu-
lation, lipid and glucose metabolism and insulin sensi-
tivity [22,23]. This adipocytokine is also known by its
anti-atherogenic and anti-inflammatory properties. Low
concentration of adiponectin was found in T2D [24]
and coronary heart disease [25]. The AdipoQ 45 T/G
polymorphism was shown to be associated with hypoa-
diponectinemia and risk of T2D in different populations
[26-28]. The STOP-NIDDM found a 1.8 times greater
risk for T2D in carriers of the variant allele [29]. Also,
associations of this SNP with other diseases included in
the spectrum of the MS have been reported [30-32].
To date, relatively few studies have investigated the
associations of common variants in the genes coding for
TNF-α, IL-6 and adiponectin with their plasma con-
centration changes following interventions on lifestyle.
Assuming that part of the heterogeneous response to life-
style interventions among populations may be explained
by genotypic factors, we investigated whether certain in-
flammation related-polymorphisms influence the response
profile of Brazilian individuals. This study assessed the
association of the TNF-α -308 G/A, IL-6 -174 G/C and
AdipoQ 45 T/G polymorphisms with changes in an-
thropometric, metabolic and inflammatory biomarkers
following a lifestyle intervention in Brazilians at high car-
diometabolic risk.
Methods
This was a 9-month intervention study on lifestyle for
prevention of T2D carried out during 2009 and 2010.
The study protocol was approved by the local ethical
committee and individuals provided informed written
consent before entering the study. Individuals aged from
18 to 80 years were screened at Healthcare Unit of the
School of Public Health, University of São Paulo, Brazil.
Those with at least one risk factor were invited to a
clinical examination and laboratory tests including a
75-gram oral glucose tolerance test. Inclusion criteria
were the presence of prediabetes (impaired fasting glu-
cose or impaired glucose tolerance according to the
American Diabetes Association [33] or MS according to
International Diabetes Federation criteria for Latin-
American populations [34]. For the purpose of this study,
two categories of skin colors was defined – white and
non-white – being the latter composed of mulattos and
blacks. Asian descendants were excluded. Those with a
medical history of neurological or psychiatric distur-
bances, thyroid, liver, renal and infectious diseases were
excluded.
The intervention on lifestyle consisted of medical con-
sultations every three months, where counseling for
changing living habits was given. Our intervention goals
were similar to those previously proposed [1,2]. Indivi-
duals also attended group sessions, where topics on
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healthy diet, physical activity and psychosocial stress
management were discussed with a multi-professional
team. At the end of the ninth month, examinations were
repeated. Compliance rate to the intervention program
did not differ between subgroups of individuals stratified
according to the genotypes.
A total of 301 individuals were eligible and 180 agreed
to participate. Thirty-seven participants lost to follow-up
and eight DNA samples with low quality that resulted in
poor genotyping calls were excluded.
Dietary data were collected using 24-hour food recalls
by trained nutritionists. Physical activity level was assessed
by the long version of the international Physical Activity
Questionnaire [35]. Individuals that achieved 150 min
per week of total physical activity were considered active.
Height was measured using a fixed stadiometer, weight
was obtained from individuals wearing light clothes and
no shoes on a Filizola digital scale and BMI was calcu-
lated. Abdominal circumference was measured at the
midpoint between the bottom of the rib cage and above
the top of the iliac crest during minimal respiration.
Venous blood samples were collected after overnight
fasting. Plasma glucose was measured by the glucose-
oxidase method and lipoproteins determined enzymati-
cally by automatic analyser. Aliquots were frozen at −80°C
for further determinations of apolipoproteins (Apo), in-
flammatory markers and for genotyping. Apo A1 and B
concentrations were determined using turbidimetry.
CRP, IL-6 and TNF-α concentrations were determined
by immunoenzyme chemiluminescent assay (Immulite,
Diagnostic Products Corporation, Los Angeles, CA, USA).
Serum insulin was determined by immunometric assay
using a quantitative chemiluminescent kit (AutoDelfia,
Perkin Elmer Life Sciences Inc, Norton, OH, USA). Adi-
ponectin was measured by ELISA (Linco Research, St.
Charles, Missouri, USA). Whole blood was used for
DNA extraction for determination of the SNPs.
Genotyping
Genomic DNA was extracted from whole blood using
the salting out method [36]. After extraction, the viability
of the extracted material was visualized in 1% agarose
gel and concentration was obtained by spectrophotom-
eter Nanodrop 8000 (Thermo Scientific, Waltham, MA,
USA). Genotyping of the TNF-α -308 G/A (rs1800629),
IL-6 -174 G/C (rs1800795) and AdipoQ 45 T/G
(rs 2241766) polymorphisms was performed using an
allele specific polymerase chain reaction (PCR) or ampli-
fication refractory mutation [37]. Detection of the pro-
ducts was made using fluorescence resonance energy
[38]. PCRs were carried out with ArrayTape instrumen-
tation, and allele calls were generated based on the
clustering of fluorescent signals. Only genotypes with a
level of confidence ≥90% were included in the analysis.
Moreover, a total of 30 duplicate samples were included
in an attempt to check for genotyping errors. The geno-
type success rates for TNF-α -308 G/A, IL-6 -174 G/C
and AdipoQ 45 T/G were 98%, 99% and 99%, respectively.
Statistical analysis
Data were expressed by means and standard deviations
(SD) or medians and interquartile intervals. The normality
of the distribution of each variable was analyzed by
Kolmogorov-Smirnov test. Log-transformation was per-
formed to obtain normal distribution of skewed variables
(insulin, adiponectin, IL-6 and CRP). Student t test (or
Wilcoxon) was used to compare means of variables be-
tween groups with and without polymorphisms. Chi-
square test was used to evaluate the Hardy-Weinberg
equilibrium (p > 0.05). Stepwise logistic regression ana-
lysis was performed to evaluate the impact of genotypes
on clinical variables changes, dichotomized by using ar-
bitrary criteria (i.e. ≥1 SD change) for improvement in
variables from baseline to 9-month examination. Each
clinical improvement (dependent variable) was used in
a separate model. Presence of the variant allele was
considered the independent variable of main interest,
adjusted for sex and age. Variables showing a p-value
<0.20 in crude analysis entered the multiple models.
Statistical analyses were performed using the SPSS
17.0 (SPSS Inc., Chicago, IL, USA) for Windows. Statistical
significance was assumed when p values were < 0.05.
Results
Among 138 individuals, 66.7% were women and 30.4%
non-white; the mean age of the sample was 56.5 (± 11.6)
years and BMI was 30.3 (± 5.6) kg/m2. A total of 62.3%
had prediabetes and 90.6% MS. After intervention, mean
values of energy intake reduced and total physical activity
elevated significantly considering the entire sample
(Table 1), as well as the subsets of individuals stratified
by the presence of the polymorphisms (data not shown).
The proportion of active individuals at the ninth month
was higher than at baseline (52.2 versus 55.6%, p <0.05).
Significant improvement in anthropometric variables,
plasma glucose, lipid profile and inflammatory markers
was observed, except for IL-6 concentrations.
Genotype groups were in Hardy-Weinberg equilibrium,
except the TNFα -308 G/A. The individuals with at least
one variant allele were grouped and compared with those
with the reference genotype.
TNFα -308 G/A polymorphism
The overall frequency of the variant allele was 12.8% and
the distribution of GG, GA, and AA genotypes was
79.4%, 15.4%, and 5.2%, respectively.
Variant A allele carriers did not improve values of waist
circumference, HDL-c and Apo A1 after intervention but
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the reference genotype group did (Table 2). Regarding
glucose metabolism, at baseline, higher fasting plasma
glucose (103.9 ± 11.2 versus 97.8 ± 11.1 mg/dL; p = 0.012)
and lower values of insulin [5.6 (4.0, 10.7) versus 9.8
(6.1, 12.0)] were observed in the A allele carriers and only
this group decreased significantly fasting plasma glu-
cose (−6.5 ± 11.8 versus −1.6 ± 14.1%; p = 0.050) after
intervention. Logistic regression analysis showed that the
presence of A allele was predictive of improvement in
fasting plasma glucose after intervention, adjusted for sex
and age (OR = 2.96, p = 0.025), but was not concerning
other metabolic benefits. The significance of this result
did not change when the presence of the other poly-
morphisms were entered in the model.
Mean values of TNF-α and CRP decreased and IL-6
increased after intervention in both genotype groups.
IL6 -174 G/C polymorphism
The overall frequency of the variant allele in sample was
46.2% and the distribution of GG, GC, and CC geno-
types was 35.0%, 37.3%, and 27.6%, respectively.
Pre- and post-intervention mean body weight values
were similar in genotype groups and waist circumference
decreased significantly only in reference group (Table 3).
Variant C allele carriers showed greater improvement
in the lipid profile after intervention than the reference
genotype group. Lower concentrations of total choles-
terol (191.5 ± 43.2 versus 209.5 ± 42.7 mg/dL, p = 0.023)
and LDL-c (115.5 ± 38.6 versus 131.8 ± 37.1 mg/dL,
p = 0.019) were observed only among the variants, who
increased significantly Apo A1 concentrations (134.3 ±
15.9 to 139.8 ± 16.8 mg/dL, p = 0.001) and had a higher
mean increment in HDL-c concentration (13.3 versus
3.0%, p = 0.043) than the reference group. On the other
hand, changes in glucose metabolism were more favor-
able in the reference genotype. The latter group
decreased fasting plasma glucose (99.4 ± 11.4 to 95.3 ±
11.9 mg/dL, p = 0.038), but not the variant allele carriers.
In both genotype groups, the intervention induced
reductions in CRP and TNF-α concentrations and in-
crease in mean IL-6 values, but only variant allele carriers
showed significant increase in adiponectin concentration.
Adipo 45 T/G polymorphism
The overall frequency of the variant allele was 14.7% and
the TT, TG and GG genotypes were 72.0%, 26.5%, and
1.5%, respectively.
Variant G allele carriers showed a worse glucose and
lipid metabolism response to intervention than the refer-
ence genotype. In contrast to reference genotype (Table 4),
the variant allele group did not decrease mean values of
fasting plasma glucose and Apo B nor increase HDL-c
values.
In both genotype groups, the intervention induced
reductions in CRP and TNF-α concentrations and in-
crease in mean IL-6 values, but only variant allele carriers
showed significant increase in adiponectin concentration
significantly.
In order to evaluate the combined impact of the poly-
morphisms in glucose metabolism, the subset of 22 indi-
viduals with the three variants associated with worse
glycemic response were grouped (TNFα -308 G + IL6
-174C +AdipoQ 45 G) and compared with the remainder.
These groups had similar mean values of anthropometric
and metabolic variables at baseline. After intervention,
the group with worse glycemic response showed a signifi-
cantly higher fasting plasma glucose levels (102.2 ± 11.6
Table 1 Mean (SD) or median (interquartile interval)
values of variables at baseline and after 9 months of
lifestyle intervention in total sample
Baseline 9 months p
Energy intake
(kcal/day)
1814 (673) 1530 (558) 0.008
Total physical activity
(min/wk)
186 (60, 262) 221 (70, 303) 0.007
Weight (kg) 78.6 (15.5) 76.7 (15.4) 0.005
Waist circumference
(cm)
99.2 (12.3) 98.1 (12.0) 0.005
Fasting plasma
glucose
(mg/dL)
99.5 (11.5) 96.7 (12.5) 0.018
2-h plasma glucose
(mg/dL)
119.3 (28.3) 113.1 (29.3) 0.009
Triglycerides
(mg/dL)
155.0 (65.5) 151.3 (71.5) 0.491
Total cholesterol
(mg/dL)
202.0 (43.6) 198.0 [3,43] 0.238
HDL-c (mg/dL) 42.5 (12.4) 46.7 (12.5) 0.001
LDL-c (mg/dL) 128.0 (40.0) 121.0 (38.4) 0.063
Apolipoprotein B
(mg/dL)
96.0 (22.6) 84.4 (24.0) 0.004
Apolipoprotein A1
(mg/dL)
136.7 (18.5) 141.1 (19.7) 0.005
Insulin* (uUl/L) 9.6 (5.6, 11.9) 6.6 (4.2, 9.9) 0.003
HOMA-IR** 2.1 (1.3, 2.9) 1.5 (1.0, 2.3) 0.008
Adiponectin*
(ng/dL)
11.8 (7.5, 18.9) 16.3 (11.5, 19.8) 0.012
Interleukin 6*
(pg/dL)
2.5 (1.3, 4.0) 3.4 (2.0, 5.5) 0.007
C-reactive protein*
(mg/dL)
0.370 (0.165, 0.617) 0.255 (0.070, 0.602) 0.036
Tumor necrosis
factor α** (pg/dL)
10.9 (9.0, 13.4) 8.8 (7.2, 10.5) 0.003
*Log-transformed for analysis.
**Non-parametric test.
HOMA-IR: homeostatic model assessment for insulin resistance.
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Table 3 Mean (SD) or median (interquartile interval) values of variables and variation after 9 months of intervention
according to IL6 -174 G/C SNP genotypes
GG (n = 47) GC + CC (n = 86)
Baseline 9 months p Baseline 9 months p
Energy intake (Kcal/day) 1748(729.6) 1481(588.0) .002 1849(649.8) 1574(549.7) .001
Total physical activity (min/wk) 140(60, 282) 240(70, 330) .001 160(60, 260) 210(70, 290) .001
Weight (kg) 76.9(15.3) 74.7(15.6) .003 78.8(15.7) 77.2(15.3) .001
Waist circumference (cm) 97.2(10.7) 95.7(11.1) .036 99.4(12.8) 98.8(12.3) .161
Fasting glucose (mg/dL) 99.4(11.4) 95.3(11.9) .038 98.9(11.3) 97.1(12.8) .233
Triglycerides (mg/dL) 161.1(60.3) 163.9(84.1) .786 151.5(69.5) 145.3(65.1) .299
Total cholesterol (mg/dL) 198.3(45.8) 209.5(42.7) .122 202.9(42.9) 191.5(43.2)† .011
HDL-c (mg/dL) 44.3(15.5) 45.6(13.6) .446 41.6(10.5) 47.2(12.1) .002
LDL-c (mg/dL) 123.1(42.7) 131.8(37.1) .251 129.4(38.9) 115.5(38.6)† .002
Apolipoprotein B (mg/dL) 95.6(23.2) 85.1(24.5) .003 95.6(22.6) 84.1(24.0) .001
Apolipoprotein A1 (mg/dL) 140.7(22.8) 143.6(24.7) .197 134.3(15.9) 139.8(16.8) .001
Insulin* (uUl/L) 8.1(5.4, 11.4) 5.7(4.0, 9.1) .004 9.7(5.6, 12.1) 7.0(4.3, 10.6) .002
Adiponectin* (ng/dL) 11.8(7.8, 19.3) 13.1(9.8, 19.7) .091 12.1(7.3, 18.6) 16.8(12.4, 19.8) .005
Interleukin 6* (pg/dL) 1.7(0.9, 3.5) 2.8(2.0, 5.4) .007 2.5(1.4, 4.6) 3.6(2.0, 5.8) .027
C-reactive protein* (mg/dL) 0.33(0.10, 0.59) 0.25(0.06, 0.64) .005 0.37(0.19, 0.58) 0.25(0.07, 0.56) .005
TNF-α** (pg/dL) 11.0(9.0, 13.7) 8.9(6.9, 10.5) .017 11.0(9.4, 13.3) 8.8(7.2, 10.6) .016
*Log-transformed for analysis.
**Non-parametric test.
† p < 0.05 versus GG.
TNF-α: Tumor necrosis factor alpha.
Table 2 Mean (SD) or median (interquartile interval) values of variables and variation after 9 months of lifestyle
intervention according to SNP TNF −308 G/A genotypes
GG (n = 107) AA + GA (n = 28)
Baseline 9 months p Baseline 9 months p
Energy intake (Kcal/day) 1851.6(685.0) 1555.4(580.6) .001 1633.6(620.9) 1449.0(488.5) .006
Total physical activity (min/wk) 167(60, 278) 205(75, 305) .002 140(30, 210) 210(60, 400) .021
Weight (kg) 79.0(15.4) 77.1(15.2) .006 76.5(16.6) 74.8(16.9) .006
Waist circumference (cm) 99.2(12.1) 98.3(11.7) .029 98.0(13.0) 96.9(13.6) .205
Fasting glucose (mg/dL) 97.8(11.1) 96.2(13.1) .233 103.9(11.2)† 97.1(9.9) .007
Triglycerides (mg/dL) 159.1(68.0) 154.2(74.6) .428 138.2(56.2) 141.7(61.9) .689
Total cholesterol (mg/dL) 200.9(42.8) 197.3(43.3) .413 202.2(47.4) 197.1(45.9) .559
HDL-c (mg/dL) 41.7(12.3) 46.7(13.2) .020 45.5(12.7) 46.3(10.0) .778
LDL-c (mg/dL) 127.3(38.9) 120.1(38.2) .097 126.8(44.6) 122.4(41.3) .647
Apolipoprotein B (mg/dL) 95.6(22.4) 84.8(23.8) .004 95.3(23.4) 82.5(25.5) .004
Apolipoprotein A1 (mg/dL) 135.8(17.8) 140.8(20.1) .005 139.7(21.7) 142.0(19.0) .443
Insulin* (uUl/L) 9.8(6.1, 12.0) 6.9(4.3, 10.5) .009 5.6(4.0, 10.7)† 5.2(3.1, 8.8) .151
Adiponectin* (ng/dL) 11.8(7.5, 18.7) 16.2(11.3, 19.4) .019 11.7(7.3, 19.1) 16.2(12.2, 20.9) .020
Interleukin 6* (pg/dL) 2.4(1.3, 3.7) 3.2(2.0, 5.2) .013 2.4(1.1, 4.9) 4.2(2.4, 9.4) .006
C-reactive protein* (mg/dL) 0.37(0.19, 0.59) 0.25(0.05, 0.55) .001 0.36(0.13, 0.94) 0.32(0.15, 0.89) .009
TNF-α** (pg/dL) 10.8(9.0, 13.2) 8.7(7.2, 10.8) .020 11.3(9.4, 13.9) 8.9(6.9, 10.2) .016
*log-transformed for analysis.
**Non-parametric test.
† p < 0.05 versus GG.
TNF-α: Tumor necrosis factor alpha.
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versus 95.7 ± 11.4 mg/dL, p = 0.025), despite similar post-
intervention anthropometric values.
Discussion
Our data showed diverse responses to lifestyle interven-
tion when analyzing the entire sample or subgroups
stratified according to the SNPs. This may suggest a role
for genotype in the response to lifestyle interventions.
Contrasting with numerous reports on the frequencies
of these three SNPs (TNF-α -308 G/A, IL6 -174 G/C
and AdipoQ 45 T/G) associated with body adiposity,
metabolic disturbances and inflammation, their associ-
ation with response to intervention on lifestyle has been
rarely investigated. Admixture of the Brazilian population
does not allow adequate classification by ethnic group;
this condition may limit the comparisons of our findings
with the same polymorphisms studied in other popula-
tions. Despite the heterogeneity of our population, the
frequencies of the variant alleles did not markedly differ
from data previously reported in literature [39-41].
The TNF-α, IL-6 and AdipoQ polymorphisms were
selected considering the participation of these cytokines
in underlying mechanisms of obesity-related metabolic
disturbances, such as inflammation and insulin resist-
ance. It is consistently demonstrated the deleterious ef-
fect of TNF-α in insulin signaling pathways [11]. Both,
TNF-α and IL-6 were shown to promote liver secretion
of inflammatory biomarkers like CRP [42]. Also, insulin-
sensitizing, anti-inflammatory and anti-atherogenic prop-
erties of adiponectin have been described [43]. Although
it is clear that TNF-α and adiponectin exert opposite
roles, findings regarding interleukins action are not so
homogeneous.
The presence of the TNF-α -308 G/A polymorphism
was associated with more favorable response of glu-
cose metabolism to intervention, despite non-significant
change in adiposity. Considering that the entire sample
lose weight, it is possible that the subset with this TNF-α
variant allele may have been protected against glucose
disturbance independent of the body adiposity. At base-
line, variant allele carriers had higher mean fasting plasma
glucose levels, and exhibited a greater decrease after inter-
vention compared with the reference group, even after
adjustments. This is in line with a case control study in a
Tunisian population, in which this SNP was not asso-
ciated with obesity or T2D [16]. However, the results of a
meta-analysis indicated no association with variant allele
and fasting plasma glucose or T2D [44].
On the other hand, other intervention-induced cardio-
metabolic benefits, such as increases in HDL-c and Apo
A1 concentrations, were not detected in variant allele
carriers but in the reference genotype group. Deleterious
effects of this TNF-α variant allele was previously sug-
gested in a meta-analysis in which individuals carrying
Table 4 Mean (SD) or median (interquartile interval) values of variables and variation after 9 months of lifestyle
intervention according to SNP AdipoQ 45 T/G genotypes
TT (n = 94) TG + GG (n = 37)
Baseline 9 months p Baseline 9 months p
Energy intake (Kcal/day) 1805(720) 1558(617) .001 1811(569) 1459(407) .001
Total physical activity (min/wk) 150(60, 260) 210(60, 300) .002 190(62, 280) 210(90, 360) .008
Weight (kg) 79.4(17.1) 77.7(16.9) .004 76.9(11.9) 74.9(12.1) .003
Waist circumference (cm) 99.7(13.5) 98.9(13.1) .077 97.9(8.8) 96.5(9.1) .061
Fasting glucose (mg/dL) 99.2(11.8) 95.7(12.8) .015 98.5(10.2) 98.8(11.3) .891
Triglycerides (mg/dL) 155.5(65.9) 146.1(61.4) .087 156.9(68.1) 166.7(95.3) .432
Total cholesterol (mg/dL) 201.3(44.5) 195.3(43.6) .167 197.7(42.6) 202.8(46.3) .555
HDL-c (mg/dL) 42.2(12.4) 47.1(128.9) .009 42.5(11.8) 44.6(10.8) .242
LDL-c (mg/dL) 126.8(40.0) 118.9(38.1) .068 125.1(41.8) 126.3(41.7) .897
Apolipoprotein B (mg/dL) 96.6(22.5) 84.3(23.8) .030 91.3(23.7) 82.9(26.0) .068
Apolipoprotein A1 (mg/dL) 136.7(19.5) 140.6(20.9) .013 135.9(17.0) 142.3(17.9) .005
Insulin* (uUl/L) 10.1(6.0, 12.5) 7.0(4.3, 10.5) .001 6.8(3.9, 10.5) 5.4(3.6, 9.2) † .005
Adiponectin* (ng/dL) 11.2(7.5, 16.2) 15.0(11.1, 18.2) .005 15.7(7.9, 22.4) 18.2(12.8, 22.4) .060
Interleukin 6* (pg/dL) 2.4(1.3, 3.7) 3.4(2.2, 5.8) .009 2.7(1.2, 4.6) 3.2(2.0, 5.1) .398
C-reactive protein* (mg/dL) 0.33(0.13, 0.58) 0.29(0.07, 0.64) .040 0.42(0.21, 0.80) 0.20(0.07, 0.48) .001
TNF-α** (pg/dL) 10.8(8.9, 13.4) 9.1(7.4, 10.8) .005 10.9(10.1, 13.2) 8.3(6.9, 10.0) .004
*Log-transformed for analysis.
**Non-parametric test.
† p = 0.054 versus TT.
TNF-α: Tumor necrosis factor alpha.
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the -308 G/A polymorphism had greater risk of obesity
and comorbidities [44].
It has been postulated that functional polymorphisms
in promoter region could affect transcription rates and
circulating levels of cytokines [45]. However, in our
sample, the presence of the -308 G/A SNP did not influ-
ence TNF-α concentration at baseline or the response
pattern to the intervention, since both genotype groups
exhibited reductions in mean values of this cytokine. This
is in agreement with a recent meta-analysis including
healthy individuals that reported lack of associations be-
tween this TNF-α SNP and circulating levels, refuting a
functional consequence of its presence [46].
In our study, some findings suggest that C allele car-
riers of the IL-6 -174 G/C polymorphism could have
obtained more benefits from the intervention on lipid
metabolism than those with the reference genotype, but
not in glucose metabolism. Only C allele carriers showed
a significant decrease in total cholesterol and LDL-c and
increase in HDL-c and Apo A1 concentrations. Cross-
sectional studies, conducted in several populations, had
already reported a worse lipid profile in the reference
genotype individuals compared with variant carriers. In
Caucasian populations, significantly higher plasma tri-
glyceride, total cholesterol and LDL-c and slightly lower
HDL-c were observed in individuals with the reference
genotype than in C variant allele carriers [17,47]. However,
the variant allele carriers did not reduce significantly fast-
ing plasma glucose but did those with reference genotype.
These contrasting results might be at least in part to a
decrease in central adiposity verified only in the reference
genotype group. Our findings are in agreement with
those obtained from a Finnish Caucasian population in
which GG genotype had lower fasting plasma glucose
than C allele carriers [17].
Both genotype groups IL-6 -174 G/C SNP responded
to the intervention with reductions in plasma TNF-α
and CRP, but with unexpected elevations in mean IL-6
concentrations. Additionally, variant allele carriers had
significant increase adiponectin concentration after
intervention. Attenuation of pro-inflammatory actions of
TNF-α and CRP and the favorable effect of adiponectin
on inflammation and insulin sensitivity, those findings
are desirable for individuals at high cardiometabolic risk
undergoing lifestyle interventions.
To our knowledge, increased circulating levels of IL-6,
particularly in carriers of IL-6 -174 G/C SNP submitted
to long-term lifestyle intervention, have not been reported.
It is known that IL-6 is released from skeletal muscle dur-
ing exercise proportionally to exercise intensity [48]. How-
ever, the increased output found in the recovery phase of
prolonged exercise is most probably from the skeletal
muscle and, to a lesser extent, from the subcutaneous
adipose tissue [49]. Our intervention program included
physical activity but the majority of the sample per-
formed light-to-moderate exercises (data not shown).
Given the fact that IL-6, more than any other cytokine,
is produced locally in the skeletal muscle in response to
exercise, it is likely that it plays a beneficial role in medi-
ating exercise-related metabolic changes [50].
Our recommendation to enhance physical activity dur-
ing the intervention was attended by the entire sample
since the proportion of active individuals increased at the
end of the intervention. Despite no correlation detected
between changes in physical activity and changes in IL-6
concentration (data not shown), we speculate that the
IL-6 elevation in our sample could be partially attributed
to exercise. This finding does not seem to reflect a pro-
inflammatory effect, since mean values of CRP reduced
significantly. Further investigations, including a large
spectrum of interleukins, are necessary to understand
their role in interventions on life habits.
The group of carriers of variant allele AdipoQ 45 T/G
SNP did not change fasting plasma glucose and adipo-
nectin concentrations but the reference genotype group
did. We speculate that the lack of increment in adipo-
nectin concentration after intervention may have con-
tributed to impede benefits in glucose metabolism in the
variant allele carriers. Controversial data have been
reported among populations [27,29,51]. Our result may
be considered somehow different from a case–control
study, since higher adiponectin concentration was found
among variant allele homozygous in healthy Korean
woman [51]. In contrast, a cross-sectional survey in
Chinese population showed lower plasma adiponectin in
variant allele carriers compared with the TT genotype
[27]. Data from the STOP-NIDDM trial [29] and a case
control study in obese Iranian population [52] are in line
with ours, since they support that variant G allele might
confer susceptibility to T2D.
Our findings indicated unfavorable effects of the vari-
ant allele of the AdipoQ 45 T/G in lipid profile, when
compared to the entire sample and to the reference
genotype group. Carriers of the G allele did not decrease
Apo B nor increase HDL-c concentrations after inter-
vention. Similarly to ours, in a Chinese cross-sectional
study, G carriers had higher total and LDL-c levels than
the reference genotype group [27]. The beneficial re-
sponse of CRP concentrations to our intervention seems
having not depended on the AdipoQ 45 T/G SNP. This
set of evidence suggests the presence of this SNP
impedes metabolic response to lifestyle interventions.
The comparison of the group the individuals with the
three variants associated with worse glycemic response
with the remainder sample could suggest that the com-
bination of polymorphisms would enhance the negative
impact on glucose metabolism. Despite similar fasting
plasma glucose at baseline, the former group finished
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the intervention with higher levels, which would be com-
patible with this hypothesis. This speculation deserves
further investigation based on large samples.
Despite the strength of addressing important SNPs co-
difying for proteins known to affect inflammatory status
and insulin sensitivity, and examining a great number of
metabolic biomarkers, our study has the limitation of
the sample size. The small sample size could be respon-
sible for the absence of Hardy-Weinberg equilibrium for
TNF -308 G/A. Actually, a study including a large sam-
ple of individuals from the same region of Brazil indi-
cated that this SNP is in HWE [53]. Another possible
explanation for such finding could be that this SNP itself
would be a risk factor for diabetes and cardiometabolic
risk. Therefore, our results should be considered prelim-
inary at best.
In summary, the TNFα -308 G/A SNP may predispose
a better response of glucose metabolism to intervention.
The IL-6 -174 G/C SNP may confer a beneficial effect
on lipid but not in glucose metabolism. Our findings
reinforce unfavorable effects of the AdipoQ 45 T/G SNP
in lipid profile and glucose metabolism after lifestyle
intervention in Brazilians at cardiometabolic risk. Fur-
ther studies on SNPs of genes involved on the control of
inflammatory status and insulin sensitivity should pro-
vide more subsidies to achieve the goals of preventing
metabolic disturbances through lifestyle changes in indi-
viduals at high cardiometabolic risk.
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